Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients | Zendy

Marijn M. Speeckaert | Zendy; Katrien Devreese | Zendy; Raymond Vanholder | Zendy; Annemieke Dhondt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients

Author(s) -

Marijn M. Speeckaert,

Katrien Devreese,

Raymond Vanholder,

Annemieke Dhondt

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft293

Subject(s) - medicine , fondaparinux , calciphylaxis , dialysis , anticoagulant , hemodialysis , heparin , vitamin k , vitamin d and neurology , coumarin , intensive care medicine , calcification , venous thromboembolism , thrombosis , botany , biology

Accelerated vascular calcification and increased risk of calciphylaxis can be a reason to restrict the use of vitamin K antagonists in dialysis patients. We describe the use of fondaparinux, a prototype indirect factor Xa inhibitor, as an alternative anticoagulant to coumarin derivatives in dialysis patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research